Koenig Sheldon L. 4
4 · Esperion Therapeutics, Inc. · Filed Mar 8, 2023
Insider Transaction Report
Form 4
Koenig Sheldon L.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-03-07$5.06/sh−5,441$27,510→ 194,815 total
Footnotes (2)
- [F1]Shares were sold to satisfy tax obligation on vested shares of performance-based restricted stock units.
- [F2]Consists of 194,815 shares of common stock held, including 1,999 shares recently acquired in Esperion's Employee Stock Purchase Plan.